Staehler M, Haseke N, Schöppler G, Stadler T, Adam C, Stief C G
Urologische Universitätsklinik, Klinikum Grosshadern der Ludwig-Maximilians-Universität München, Marchioninistrasse 15, 81377 Munich.
Urologe A. 2006 Jan;45(1):99-110, quiz 111-2. doi: 10.1007/s00120-005-0982-6.
The therapeutic regimen for metastatic renal cell cancer has changed substantially in the last years. Formerly, metastatic disease was regarded as being inoperable and had a disastrous prognosis. Nowadays, radical nephrectomy is the accepted urologic-oncologic standard therapy in metastatic primaries, if technically feasible. A complete resection of metastases may be curative, or can achieve a substantial palliative benefit. A better understanding of prognostic parameters helps in the selection of patients with a chance of benefiting from systemic immunochemotherapy. For patients with rapidly progressing tumors or sarcomatoid dedifferentiation, new effective chemotherapy regimens are available. New angiogenesis inhibitors such as sutent, avastin or sorafenib can potentially be effectively used in future therapeutic regimens.
在过去几年中,转移性肾细胞癌的治疗方案发生了显著变化。以前,转移性疾病被认为无法手术,预后很差。如今,如果技术上可行,根治性肾切除术是转移性原发性肿瘤公认的泌尿肿瘤学标准治疗方法。完全切除转移灶可能治愈疾病,或可带来显著的姑息性益处。更好地了解预后参数有助于选择有可能从全身免疫化疗中获益的患者。对于肿瘤进展迅速或肉瘤样去分化的患者,有新的有效化疗方案可供选择。新型血管生成抑制剂,如索坦、阿瓦斯汀或索拉非尼,可能会在未来的治疗方案中得到有效应用。